USE OF VITAMIN E COMPOUND - HUIYU HEALTH HANGZHOU PHARMACEUTICAL TECH CO LTD

Title:

USE OF VITAMIN E COMPOUND

Document Type and Number:

WIPO Patent Application WO/2021/077990

Kind Code:

A1

Abstract:

A use of a vitamin E compound in the preparation of a drug for down-regulating the level of oxidative stress caused by an anti-tumor drug, a use of a vitamin E compound in combination with an anti-tumor drug in the preparation of a drug for improving immunity, and a use of a vitamin E compound in the preparation of a drug for alleviating bone marrow suppression caused by an antitumor drug or alleviating hemolytic disorders caused by an antitumor drug.

More Like This:

JP5998351	Prevention of a snore, or the constituent for an improvement
JP2015091246	METHOD FOR ENHANCING QUALITY OF LIFE OF SENIOR ANIMAL
JP6646578	Polymer-Carbohydrate Conjugates for Drug Transfer Technology

Inventors:

LI QINGPO (CN)
JIANG XINDONG (CN)
JIN ZHAOLEI (CN)
QIU WEIGEN (CN)

Application Number:

PCT/CN2020/118187

Publication Date:

April 29, 2021

Filing Date:

September 27, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

HUIYU HEALTH HANGZHOU PHARMACEUTICAL TECH CO LTD (CN)

International Classes:

A61K31/355; A61K9/10; A61K31/337; A61P35/00

Domestic Patent References:

WO2009002425A2

2008-12-31

Foreign References:

CN105534904A	2016-05-04
CN105534903A	2016-05-04
CN103520151A	2014-01-22
CN105560182A	2016-05-11
CN104224710A	2014-12-24
CN101632635A	2010-01-27
CN102871963A	2013-01-16
CN109966250A	2019-07-05

Other References:

ZHANG LIN, LIU FUYOU, PENG YOUMING, LI DAWEI, ZENG NI, WU RONG, LIU CANGSANG: "The Effect of Vitamin E on Cisplatin Induced Nephrotoxicity in Mice and its Mechanism", ANTI-TUMOR PHARMACY, EDITORIAL DEPARTMENT OF ANTI-TUMOR PHARMACY, CN, vol. 2, no. 5, 1 October 2012 (2012-10-01), CN, pages 343 - 350, XP055803806, ISSN: 2095-1264, DOI: 10.3969/j.issn.2095-1264.2012.05.004
CRUZ SILVA, M.M. MADEIRA, V.M.C. ALMEIDA, L.M. CUSTODIO, J.B.A.: "Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure", BBA - BIOMEMBRANES ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1464, no. 1, 15 March 2000 (2000-03-15), AMSTERDAM, NL, pages 49 - 61, XP004273173, ISSN: 0005-2736, DOI: 10.1016/S0005-2736(99)00237-0

Attorney, Agent or Firm:

BEIJING TANLULAI PATENT AGENT LTD (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD AND DEVICE FOR MAKING RECOMMENDATION, COMPUTER DEVICE, AND STORAGE MEDIUM

Next Patent: MESSAGE DETECTION METHOD, CONNECTIVITY NEGOTIATION RELATIONSHIP ESTABLISHMENT METHOD, AND RELATED DE...